NVCR News and Press, NovoCure Limited From 07/24/20

In this episode of Industry Focus: Wildcard , Jason Moser chats with Motley Fool analyst Brian Feroldi about three promising healthcare stocks that he personally bought. Discover their innovative products, which facilitate easy and quick diagnosis of peripheral artery disease -- plus, a "medi...

Novocure ( NVCR +5.6% ) has enrolled first patient in its Phase 2 pivotal (EF-33) trial of Tumor Treating Fields delivered utilizing high-intensity arrays in patients with recurrent glioblastoma (GBM). More news on: NovoCure Limited, Healthcare stocks news, Read more .....

EF-33 will test the potential incremental survival benefit of Tumor Treating Fields delivered using high-intensity arrays in patients with recurrent glioblastoma Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in its EF-33 phase 2 pilot trial of Tumor T...

Brief investment pitch This disruptive medtech player in oncology is up >7x since I started covering it on Seeking Alpha in 2016 (when it was trading at $7.76/share). I wrote the title in my initiation article as ' NovoC ure's TTFields Therapy Could Become The Standard Adjunct Therap...

The FDA designates privately held Denovo Biopharma 's lead candidate DB102 (enzastaurin) for Fast Track review for the treatment of newly diagnosed glioblastoma , an aggressive cancer of the brain or spinal cord. More news on: Eli Lilly and Company, MediciNova, Inc., ZIOPHARM Oncology,...

Novocure (NASDAQ: NVCR ) will collaborate with Merck (NYSE: MRK ) on a Phase 2 pilot study evaluating the concomitant use of Tumor Treating Fields and Keytruda (pembrolizumab) in PD-L1-positive non-small cell lung cancer (NSCLC) patients in a first-line setting. More news on: NovoCur...

Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.), through a subsidiary, to develop Tumor Treating Fields together with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for treatmen...

Apellis Reports Completion of Enrollment for Two Phase 3 Studies Apellis Pharmaceuticals Inc. ( APLS ) reported that it has completed enrollment for two of its Phase 3 studies which are DERBY and OAKS. Both the studies are designed to evaluate intravitreal pegcetacoplan for treating geog...

I'm a picky investor. I buy only the highest-quality growth stocks I can find. I look for companies that are rapidly improving their financial statements, boast a strong competitive position, have a huge growth runway ahead of them, and are trading at an attractive valuation. I believe Novo...

The last patient has been enrolled in Novocure's (NASDAQ: NVCR ) HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer. Final data collection will occur in six months. More news on: NovoCure Limited, Healt...